Attorney Docket No. 08702.0009-01

Application No. 09/512,701

- 24. (New) The method of elaim 16, wherein the antibody binds to a 35 kD subunit of 11-12.
- 25. (New) The method of claim 16, wherein said antagonist is administered in a dose of from about 0.05 to about 25 mg/kg.
- 26. (New) The method of claim 16, wherein said antagonist is administered in a dose of from about 0.2 to about 2 mg/kg.
- 27. (New) The method of claim 16, wherein said antagonist is administered intravenously.
- 28. (New) The method of claim 16, wherein said antagonist is administered subcutaneously.
- 29. (New) The method of claim 16, wherein said antagonist is administered cutaneously.
- 30. (New) The method of claim 16, wherein said antagonist is administered in combination with other therapies for autoimmune conditions.
- 31. (New) The method of claim 30, wherein said therapies comprise steroidal or other anti-inflammatory therapies.

<u>REMARKS</u>

STATUS OF THE CLAIMS

Claims 10-31 are pending. Claims 10-15 have withdrawn as directed to nonelected subject matter. Claims 16-20 have been rejected. New claims 21-31 have been added. Support for claim 21 can be found e.g., on page 7 of the present specification. Support for claims 22-24 can be found e.g., on page 8 of the present

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com